Partial
Partially Aligned
Patient Risk:
Low
Summary
One of three AI claims is supported by the label (active ingredient). The dosing and generic-status claims are not verifiable from the provided label content.
Category Scores
Accurate Statements
Rinvoq is upadacitinib.
Label DESCRIPTION states 'RINVOQ and RINVOQ LQ are formulated with upadacitinib' (Section 11).
Unsupported Statements
In the United States, typical dosing is 15 mg once daily.
Label excerpt provided does not include explicit dosing information; Section 2 (DOSAGE AND ADMINISTRATION) content is not shown in the prompt.
There is no generic version yet.
Label content provided does not address generic availability; no statement about generics is present in the excerpt.
Contradictions
Important Omissions
Indication (approved uses) and full dosing regimen details from Section 2; safety-related content (boxed warnings, precautions) and other label sections not provided in the prompt.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Evaluation focuses on label claims without evaluating safety signals.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Partially Aligned
Primary Issue
Dosing assertion not verifiable from the provided label content; generic status not addressed.
Suggested Improvement
Confirm and cite Section 2 (DOSAGE AND ADMINISTRATION) dosing details for the 15 mg daily regimen and verify whether generic versions are discussed in any labeling or regulatory communications.